002932 *ST明德生物
按盤價 
15.330 +0.040 (+0.262%)
15.330 +0.040 (+0.262%) | 2026/06 - 中期 | 2025/12 | 2024/12 | 2023/12 | 2022/12 | 盈利能力分析 |
| 淨資產收益率 ROE (%) | -0.402 | -0.290 | 1.257 | 1.196 | 90.614 |
| 總資產報酬率 ROA (%) | -0.372 | -0.262 | 1.066 | 0.904 | 66.739 |
| 投入資產回報率 ROIC (%) | -0.396 | -0.285 | 1.232 | 1.134 | 84.568 | 邊際利潤分析 |
| 銷售毛利率 (%) | 45.817 | 36.165 | 53.891 | 54.278 | 66.846 |
| 營業利潤率 (%) | -7.761 | -29.571 | 11.766 | 19.371 | 48.240 |
| 息稅前利潤/營業總收入 (%) | -8.204 | -24.465 | 6.530 | 19.356 | 47.876 |
| 淨利潤/營業總收入 (%) | -14.934 | -28.317 | 7.589 | 9.235 | 41.600 | 收益指標分析 |
| 經營活動淨收益/利潤總額(%) | 222.300 | 209.087 | -254.385 | 21.010 | 118.847 |
| 價值變動淨收益/利潤總額(%) | -261.293 | -162.969 | 417.818 | 89.456 | 0.746 |
| 營業外收支淨額/利潤總額(%) | 27.332 | -22.873 | -27.057 | -3.792 | -0.068 | 償債能力分析 |
| 流動比率 (X) | 18.626 | 19.433 | 4.835 | 2.698 | 3.248 |
| 速動比率 (X) | 18.159 | 19.162 | 4.669 | 2.571 | 3.139 |
| 資產負債率 (%) | 5.232 | 5.427 | 8.712 | 14.817 | 26.349 |
| 帶息債務/全部投入資本 (%) | 0.406 | 0.027 | 0.411 | 1.131 | 6.906 |
| 股東權益/帶息債務 (%) | 24,290.623 | 361,385.863 | 23,884.636 | 8,631.677 | 1,336.184 |
| 股東權益/負債合計 (%) | 1,771.388 | 1,703.359 | 1,014.342 | 550.562 | 268.294 |
| 利息保障倍數 (X) | -3.314 | 61.277 | -2.392 | 27.931 | -144.295 | 營運能力分析 |
| 應收賬款周轉天數 (天) | 536.977 | 835.792 | 1,014.913 | 905.102 | 56.380 |
| 存貨周轉天數 (天) | 208.298 | 156.791 | 235.376 | 203.374 | 27.998 |
| 備註： | 報價延遲最少15分鐘，資料更新時間為 28/08/2026 16:30 |
- 經濟通
- 強化版MQ
- 強化版TQ
- 財曆
- Mobile
Web
